Suppr超能文献

正电子发射断层扫描用 [¹¹C]DAA1106 检测轻度认知障碍-痴呆转化者外周苯二氮䓬受体结合增加。

Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [¹¹C]DAA1106.

机构信息

Clinical Neuroimaging Section, Department of Molecular Neuroimaging, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan.

出版信息

Psychiatry Res. 2012 Jul 30;203(1):67-74. doi: 10.1016/j.pscychresns.2011.08.013. Epub 2012 Aug 11.

Abstract

Subjects with mild cognitive impairment (MCI) have "prodromal or incipient" dementia with neuropathological changes. Peripheral benzodiazepine receptor (PBR) binding was shown to reflect activated microglia, one of the predictive biomarkers of conversion to dementia. We sought to evaluate PBR binding in MCI subjects using positron emission tomography (PET). PET scans with [¹¹C]DAA1106, a potent and selective ligand for PBR, were performed on seven MCI subjects, 10 patients with Alzheimer's disease (AD) and 10 age-matched control subjects. PBR binding in the regions of interest was quantified by binding potential (BP). Five MCI subjects were clinically followed for 5 years after their initial PET scans. [¹¹C]DAA1106 binding to PBR was significantly increased in widespread areas in MCI subjects when compared to healthy controls. We found no significant difference in BP between MCI and AD patients. MCI subjects with [¹¹C]DAA1106 binding values higher than the control mean +0.5 standard deviation (S.D.) developed dementia within 5 years. Our finding of higher DAA binding in MCI subjects indicated that microglial activation may occur before the onset of dementia. In vivo detection of microglial activation may provide useful prognostic information with respect to stratifying MCI subjects at increased risk of dementia.

摘要

轻度认知障碍(MCI)患者具有“前驱或初期”痴呆症和神经病理学变化。外周苯二氮䓬受体(PBR)结合被证明反映了激活的小胶质细胞,这是转化为痴呆症的预测生物标志物之一。我们试图使用正电子发射断层扫描(PET)评估 MCI 患者的 PBR 结合情况。对 7 名 MCI 患者、10 名阿尔茨海默病(AD)患者和 10 名年龄匹配的对照组患者进行了 [¹¹C]DAA1106 的 PET 扫描,[¹¹C]DAA1106 是 PBR 的一种有效和选择性配体。通过结合势(BP)定量了感兴趣区域的 PBR 结合。在最初的 PET 扫描后,对 5 名 MCI 患者进行了 5 年的临床随访。与健康对照组相比,MCI 患者的 PBR 结合在广泛的区域显著增加。我们发现 MCI 患者与 AD 患者之间的 BP 没有显著差异。在 5 年内,MCI 患者的 [¹¹C]DAA1106 结合值高于对照组平均值+0.5 标准差(S.D.)发展为痴呆症。我们发现 MCI 患者的 DAA 结合更高,这表明小胶质细胞激活可能发生在痴呆症发作之前。体内检测小胶质细胞激活可能为 MCI 患者提供有用的预后信息,有助于对痴呆风险增加的 MCI 患者进行分层。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验